JAJeong-Yeal Ahn

Jeong-Yeal Ahn

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jeong-Yeal Ahn has a total of 135 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Essential Data Elements for Laboratory Test Interoperability: An Expert Consensus-Based Framework

    by Ha Nui Kim, Min-Sun Kim, Sollip Kim, Kuenyoul Park, Eun-Jung Cho, Hyejin Ryu, YeJin Oh, Shinae Yu, John Hoon Rim, Sang-Mi Kim, et al.

    Ha Nui Kim, M.D., Min-Sun Kim, M.D., Sollip Kim, M.D., Kuenyoul Park, M.D., Eun-Jung Cho, M.D., Hyejin Ryu, M.D., YeJin Oh, M.D., Shinae Yu, M.D., John Hoon Rim, M.D., Sang-Mi Kim, M.D., Geon Park, M.D., Jaehyeon Lee, M.D., Hyun-Seung Lee, M.D., Hyun-Woo Choi, M.D., You Kyoung Lee, M.D., Jeong Hwan Shin, M.D., Sang-Guk Lee, M.D., Young Kyung Lee, M.D., Jeong-Yeal Ahn, M.D., Sail Chun, M.D., Jungchan Park, M.D., Jong-Yeup Kim, M.D., Hye Hyeon Kim, Ph.D., AeKyung Kwon, M.S., Kyunghoon Lee, M.D., Yeo-Min Yun, M.D., Dongheui An, M.D., Soyoun Shin, M.D., HyunYoung Ji, M.D., On behalf of the Standardization Management Committee of the Laboratory Medicine Foundation, and On behalf of the Clinical Practice Guidelines Committee of the Korean Society for Laboratory Medicine. Ann Lab Med -0001;0:. https://doi.org/10.3343/alm.2026.0051


  • Open Access

    Evaluation of Marker Gene-Based In Silico Antimicrobial Resistance Prediction Tools

    by Woo Jin Kim, Chorong Hahm, Dongin Kim, Daewon Kim, Ja Young Seo, Jeong Yeal Ahn, Pil Whan Park, Yiel Hea Seo, Joohee Lee

    The monitoring and surveillance of antimicrobial resistance (AMR) is an important procedure in clinical patient management and epidemiological public health. Conventionally, culture-based tools such as disk diffusion methods or broth dilution methods for antibiotic susceptibility tests are used. While culture-independent approaches, such as PICRUSt2, Tax4Fun, or MicFunPred, have recently been tried based on predictive functional profiling using the 16S rRNA marker gene, evaluations of AMR tools are scarce. A total of 20 E. coli strains (Carbapenem-resistant (CRE) positive: 10, CRE negative: 10) were used. The AMR phenotype was based on Vitek2 (bioMerieux). DNA was extracted from the 20 strains, and 16S rRNA (V3-V4 region) and shotgun sequencing was carried out. The bioinformatic pipelines were QIIM2 for 16S rRNA and MetaPhlAn4 for shotgun. The functional prediction tools were PICRUSt2, Tax4Fun, and MicFunPred for 16S rRNA and AMRFinderPlus for shotgun. The presence/absence of 23 KEGG numbers regarding AMR in PICRUSt2, Tax4Fun, and MicFunPred were compared to shotgun AMR profiles. The F1 scores were calculated according to each 16S marker gene-based prediction tool using a confusion matrix. A total of 12 classes of antibiotics, including carbapenem, were analyzed. The F1 scores of 16S predictive functional profilers regarding AMR were 0.22 for Tax4Fun, 0.12 for PICRUSt2, and 0.08 for MicFunPred. While Tax4Fun showed the highest F1 score of the three 16S predictive functional profilers, the F1 scores were generally low. Our study highlights the necessity of integrating specialized AMR databases and improving algorithmic approaches to achieve meaningful accuracy in resistance prediction.


  • Analysis of blood culture data at a university hospital: bacterial distribution and cumulative antimicrobial resistance (2016–2020)

    by Yiel Hea Seo, Daewon Kim, Hwan Tae Lee, Ja Young Seo, Jeong Yeal Ahn, Pil Whan Park

    Background: The distribution of bacteria isolated from bloodstream infections and cumulative antimicrobial susceptibility data are the basis for empirical decisions regarding antibiotics as an initial treatment. Therefore, it is important to consistently collect blood culture results of individual patients and analyze them correctly. Methods: The blood culture results of patients at Gachon University Gil Medical Center from 2016 to 2020 were analyzed retrospectively to determine the bacterial distributions and antibiotic resistance patterns. Duplicates were eliminated by including only the first isolate of each species per patient. Results: Escherichia coli (27.1%) was the most commonly isolated bacterium from blood cultures, followed by Klebsiella pneumoniae (10.1%) and Staphylococcus aureus (8.6%). The methicillin resistance rate of S. aureus was 49.2%, and the vancomycin resistance rate of Enterococcus faecium was 39.5%; with no significant changes over the study period. The cefotaxime, ciprofloxacin, and ertapenem resistance rates of E. coli were 35.0%, 46.8%, and 0.7%, respectively. Seventeen carbapenem-resistant E. coli strains were isolated, of which 11 produced carbapenemase. The cefotaxime, ciprofloxacin, and ertapenem resistance rates of K. pneumoniae were 29.5%, 31.7%, and 5.4%, respectively. Forty-eight carbapenem-resistant K. pneumoniae strains were isolated, of which 37 produced carbapenemase. The imipenem resistance rates of Acinetobacter baumannii and Pseudomonas aeruginosa were 72.3% and 23.4%, respectively. Conclusion: In the blood culture results from 2016 to 2020, the isolation frequency of E. coli, K. pneumoniae, and E. faecium showed an increasing trend, whereas that of S. aureus was stable. Over the 5 year study period, the ciprofloxacin resistance rate of E. coli and P. aeruginosa and ampicillin/sulbactam resistance rate of A. baumannii significantly increased.

  • Short-Term (6 Weeks) Experience of a Modular Workcell for Hemostasis Testing Including an Intelligent Data Manager at a Tertiary Care Hospital

    by Hwan Tae Lee, So Young Lee, Ja Young Seo, Jeong-Yeal Ahn

    Objective: Modular workcells could be a better solution than total laboratory automation (TLA) in hemostasis laboratories. Here, we evaluated the impact of implementing a modular workcell (HemoCell) with an intelligent data management facility (HemoHub). Methods: We compared the turnaround times (TATs), numbers of rerun samples, and rerun times pre- and postimplementation of the HemoCell at Gil Medical Center. Prothrombin time (PT), activated partial thromboplastin time (aPTT), D-dimer, and fibrinogen were evaluated. Results: The TAT standard deviations (SDs) and maximum TAT values decreased after HemoCell implementation, although the mean TATs for PT, aPTT, and D-dimer were increased. Numbers of rerun samples were increased (18.1/day vs 44.7/day). However, rerun times were reduced, and SDs were decreased during the post-HemoCell period compared with pre-HemoCell. Additionally, technologists needed smaller working space and less labor. Conclusion: The modular workcell could improve quality and efficiency by providing more consistent TATs and shorter rerun times in the hemostasis laboratory.


  • Open Access

    Guidelines for Mobile Laboratories for Molecular Diagnostic Testing of COVID-19

    by Kyoung Ho Roh, Ki Ho Hong, Myung-Hyun Nam, Taek Soo Kim, Moon-Woo Seong, Jin Kyung Lee, Sookyoung Bae, Hee Jae Huh, Jeong-Yeal Ahn, Jinsook Lim, et al.

    Kyoung Ho Roh, M.D., Ki Ho Hong, M.D., Myung-Hyun Nam, M.D., Taek Soo Kim, M.D., Moon-Woo Seong, M.D., Jin Kyung Lee, M.D., Sookyoung Bae, M.D., Hee Jae Huh, M.D., Jeong-Yeal Ahn, M.D., Jinsook Lim, M.D., Gab Jung Kim, Ph.D., Jae Sun Park, Ph.D., Hyun Yeong Kim, Ph.D., Cheon Kwon Yoo, Ph.D., and Hyukmin Lee, M.D. on behalf of Korean Society for Laboratory Medicine, COVID-19 Task Force, and the Bureau of Infectious Disease Diagnosis Control, Korea Disease Control and Prevention Agency. Ann Lab Med 2022;42:507-14. https://doi.org/10.3343/alm.2022.42.5.507


  • Frequencies of glycosylphosphatidylinositol (GPI)-deficient cells using high-sensitivity flow cytometry as per the 2018 ICCS/ESCCA consensus guideline in patients with hematologic malignancy, aplastic anemia, or cytopenia

    by Woo-Jae Kwoun, Hwan Tae Lee, Jeong-Yeal Ahn

    We examined the frequencies and sizes of glycosylphosphatidylinositol(GPI)-deficient cells as per the International Clinical Cytometry Society/European Society for Clinical Cell Analysis(ICCS/ESCCA...

  • Open Access

    Genotypic and Phenotypic Characteristics of Hereditary Leiomyomatosis and Renal Cell Cancer Syndrome in Korean Patients

    by Ja Young Seo, Jeong-Yeal Ahn, Bhumsuk Keam, Miso Kim, Shinkyo Yoon, Jae Lyun Lee, Kwonoh Park, Inkeun Park, M.D., Ph.D.

    Ja Young Seo, M.D., Ph.D., Jeong-Yeal Ahn, M.D., Ph.D., Bhumsuk Keam, M.D., Ph.D., Miso Kim, M.D., Shinkyo Yoon, M.D., Ph.D., Jae Lyun Lee, M.D., Ph.D., Kwonoh Park, M.D., Ph.D., and Inkeun Park, M.D., Ph.D.. Ann Lab Med 2021;41:207-13. https://doi.org/10.3343/alm.2021.41.2.207


  • Open Access

    Performance of Copeptin for Early Diagnosis of Acute Myocardial Infarction in an Emergency Department Setting

    by Ji Hun Jeong, Yiel Hea Seo, Jeong Yeal Ahn, Kyung Hee Kim, Ja Young Seo, Ka Yeong Chun, Yong Su Lim, Pil Whan Park

    Jeong JH, et al. Ann Lab Med. 2020 Jan;40(1):7-14. https://doi.org/10.3343/alm.2020.40.1.7


  • Open Access

    Evaluation of global laboratory methods and establishing on‐therapy ranges for monitoring apixaban and rivaroxaban: Experience at a single institution

    by Soon Ho Park, Yiel‐Hea Seo, Pil‐Whan Park, Kyung‐Hee Kim, Ja Young Seo, Hwan Tae Lee, Woo‐Jae Kwoun, Jeong‐Yeal Ahn

    Background: Apixaban and rivaroxaban are approved for the prevention and treatment of deep vein thrombosis (DVT), pulmonary embolism (PE), and embolic stroke in atrial fibrillation (AF) patients. The aim of this study was to find appropriate methods of monitoring the anticoagulant effects of are direct oral anticoagulants (DOACs) and establish on‐therapy ranges using conventional tests.Methods: A total of 184 samples were collected from 91 patients receiving DOACs. Concentrations of apixaban and rivaroxaban in plasma were accessed by an anti‐factor Xa chromogenic assay. PT, APTT, antithrombin, D‐dimer, dRVVT screen/confirm, FDP, and fibrinogen levels were measured. On‐therapy ranges were calculated by substituting previously reported trough plasma concentrations of DOACs.Results: Anti‐factor Xa chromogenic assay‐based DOACs levels were 26.0‐279.5 (115.9 ± 56.5) ng/mL for apixaban at 2.5 mg BID, 19.9‐565.1 (205.3 ± 162.4) ng/mL for apixaban at 5 mg BID, 2.3‐395.3 (205.3 ± 162.4) ng/mL for rivaroxaban at 15 mg OD, 3.6‐494.8 (119.6 ± 95.1) ng/mL for rivaroxaban at 20 mg OD, and 9.6‐431.4 (140.8 ± 113.6) ng/mL for rivaroxaban at 15 mg BID. PT (%), antithrombin, and dRVVT confirm tests showed good correlation with plasma apixaban levels. Plasma rivaroxaban concentrations were correlated well with PT (sec), PT (%),and dRVVT confirm results. On‐therapy ranges established for dRVVT confirm test by linear regression were as follows: 1.32‐1.52 for apixaban 2.5 mg BID, 1.12‐1.75 for apixaban 5 mg BID, 1.11‐1.78 for rivaroxaban 15 mg OD, 1.09‐1.64 for rivaroxaban 20 mg OD, and 1.22‐1.81 for rivaroxaban 20 mg BID.Conclusions: Apixaban concentrations were well correlated with PT (%), antithrombin, and dRVVT confirm test. Rivaroxaban concentrations showed good correlation with PT (sec), PT (%), and dRVVT confirm test.